multiple therapies, one virus.KALIVIR is developing cutting edge, next-generation oncolytic viral immunotherapy programs for treatment of cancer. LEARN MORE NEWS AND EVENTSNovember 19, 2025 - KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors READ MORE PRESENTATIONSNovel Vaccinia Enhanced Template (VET)